Fast-growing pancreatic neuroendocrine carcinoma in a patient with multiple endocrine neoplasia type 1: a case report
Fast-growing pancreatic neuroendocrine carcinoma in a patient with multiple endocrine neoplasia type 1: a case report
Published: December 2009
Abstract
Introduction
Predictive genetic screening and regular screening programs in patients with multiple endocrine neoplasia type 1 are intended to detect and treat malignant tumors at the earliest stage possible. Malignant neuroendocrine pancreatic tumors are the most frequent cause of death in these patients. However, the extent and intervals of screening in patients with multiple endocrine neoplasia type 1 are controversial as neuroendocrine tumors are usually slow growing. Here we report the case of a patient who developed a fast-growing neuroendocrine carcinoma within 15 months of a laparoscopic distal pancreatic resection.
Case presentation
We followed a group of 45 patients with multiple endocrine neoplasia type 1 by an annual screening program in the Department of Visceral, Thoracic, and Vascular Surgery at the University Hospital Marburg in cooperation with the Department of Radiology and the Division of Endocrinology. A man with multiple endocrine neoplasia type 1 who was diagnosed with a recurrent primary
hyperparathyroidism underwent a distal pancreatic resection for a non-functional neuroendocrine tumor. In the context of our regular screening program, a large non-functional neuroendocrine tumor was diagnosed in the pancreatic head 15 months after the first pancreatic surgery. Therefore, we performed an enucleation and regional lymph node resection. At histology, the diagnosis of a neuroendocrine carcinoma with one lymph node metastasis was established. There was no evidence of recurrence 9 months after re-operation.
Conclusion
Fast-growing neuroendocrine tumors are rare in patients with multiple endocrine neoplasia type 1. The intervals, both postoperative and in newly diagnosed pancreatic lesions, in patients with multiple endocrine neoplasia type 1 should be reduced to 6 months to establish the early diagnosis of rapidly progressive disease in a small subset of patients.
Introduction
Multiple endocrine neoplasia type 1 syndrome (MEN1) is an inherited tumor syndrome, which is typically characterized by tumors of the parathyroid glands, the pancreas and the pituitary. Organs such as the adrenal glands, the thymus, the skin and the bronchial tree are involved less frequently [1-4]. Pancreatoduodenal endocrine tumors (PETs) are determinants of long-term survival. About one-third of patients with MEN1 develop malignant tumors [5,6]. Predictive genetic screening and regular screening programs are designed to detect and treat malignant tumors at the earliest stage possible. However, the extent and intervals of screening in patients with MEN1 are controversial. Current recommendations are based on the National Institutes of Health (NIH) consensus conference in 2001 [7]. A yearly biochemical screening and a tumor imaging every 3 to 5 years are emphasized. In the past few years, endoscopic ultrasound has gained importance in the detection of PETs [8,9], particularly in the setting of a prospective screening program. To date, the survival benefit of periodic screening and early intervention has not been proven.
pancreatic neuroendocrine carcinoma, multiple endocrine neoplasia type 1, MEN syndrome 1, pancreatic carcinoma, gastric neuroendocrine carcinoma, pancreatic carcinoma chemotherapy,






